0001104659-25-101869.txt : 20251023 0001104659-25-101869.hdr.sgml : 20251023 20251023165742 ACCESSION NUMBER: 0001104659-25-101869 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251023 DATE AS OF CHANGE: 20251023 EFFECTIVENESS DATE: 20251023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Quoin Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001671502 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-561902 FILM NUMBER: 251413690 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 23 HATA'AS STREET CITY: KFAR SABA PROVINCE COUNTRY: L3 ZIP: 44425 BUSINESS PHONE: 97299741444 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 23 HATA'AS STREET CITY: KFAR SABA PROVINCE COUNTRY: L3 ZIP: 44425 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biotechnology Ltd. DATE OF NAME CHANGE: 20160721 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biomed Ltd. DATE OF NAME CHANGE: 20160406 D 1 primary_doc.xml X0708 D LIVE 0001671502 Quoin Pharmaceuticals, Ltd. 42127 PLEASANT FOREST COURT ASHBURN VA VIRGINIA 20148-7349 (703) 980-4182 ISRAEL None Cellect Biotechnology Ltd. Cellect Biomed Ltd. Corporation true Michael Myers 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Executive Officer Director Sally Bridget Lawlor 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Executive Officer Denise Carter 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Executive Officer Director Joseph Cooper 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Director James Culverwell 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Director Dennis Langer 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Director Natalie Leong 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Director Michael Sember 42127 Pleasant Forest Court Ashburn VA VIRGINIA 20148 Director Pharmaceuticals Decline to Disclose 06b false 2025-10-14 false true true false 0 Maxim Group LLC 000120708 None None 300 PARK AVENUE 16th Floor New York NY NEW YORK 10022 CA CALIFORNIA CT CONNECTICUT DE DELAWARE KY KENTUCKY MD MARYLAND NV NEVADA NJ NEW JERSEY NY NEW YORK TX TEXAS true 105254891 105254891 0 The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement. false 27 1227995 true 0 Estimated commissions and fees paid at closing include cash fee of 7% of aggregate gross proceeds of private placement (except no cash fee paid for securities purchased by a Company director) and up to $75,000 for legal and other out-of-pocket expenses. 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers false Quoin Pharmaceuticals, Ltd. /s/ Dr. Michael Myers Dr. Michael Myers Chief Executive Officer 2025-10-23